洁特生物实控人方拟减持 2020年上市2募资共8.5亿

Core Viewpoint - The announcement from Jiet Bio (688026.SH) regarding a share reduction plan by its shareholder, Guangzhou Luogang District Huizi Investment Management Partnership, indicates a planned reduction of up to 186,315 shares, representing no more than 0.1327% of the company's total share capital, due to the shareholder's personal funding needs [1][2]. Group 1: Shareholder Reduction Plan - The shareholder, Huizi Investment, plans to reduce its holdings through centralized bidding from July 2, 2025, to October 1, 2025 [1][2]. - The total shares held by Huizi Investment before the reduction is 1,396,950 shares, which accounts for 1.00% of the company's total share capital [2]. - The shares intended for reduction were acquired before the IPO and through capital reserve conversion [2]. Group 2: Company Background - Jiet Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 22, 2020, with an issuance of 25 million shares at a price of 16.49 yuan per share [3]. - The company raised a total of 412.25 million yuan from its initial public offering, with a net amount of 379.41 million yuan after deducting issuance costs [3][5]. - The company has conducted two fundraising activities, totaling 852.25 million yuan [5]. Group 3: Financial Information - The company issued convertible bonds approved by the China Securities Regulatory Commission, raising a total of 440 million yuan, with a net amount of approximately 432.49 million yuan after expenses [4]. - The company distributed cash dividends of 0.6 yuan per share and increased its capital stock by 0.4 shares per share based on a total share capital of 100 million shares prior to the distribution [6].